Five years experience on 3,4-diaminopyridine phosphate in Lambert–Eaton syndrome: Case reports

RATIONALE: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. PATIENT CONCERNS: Patients have...

Descripción completa

Detalles Bibliográficos
Autores principales: Portaro, Simona, Brizzi, Teresa, Sinicropi, Stefano, Cacciola, Alberto, De Cola, Maria Cristina, Bramanti, Alessia, Milardi, Demetrio, Lupica, Antonino, Bramanti, Placido, Toscano, Antonio, Rodolico, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617689/
https://www.ncbi.nlm.nih.gov/pubmed/28930822
http://dx.doi.org/10.1097/MD.0000000000007839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617689/
https://www.ncbi.nlm.nih.gov/pubmed/28930822
http://dx.doi.org/10.1097/MD.0000000000007839

Ejemplares similares